Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

- PMLiVE

Daily Brief: EULAR kicks off, Brexit lurches closer and Autolus prepares for IPO

A rapid round up of today's pharma, biotech and healthcare news

- PMLiVE

GSK’s vaccines president Debruyne heads for the exit

Roger Connor to take on the role in latest shake up

- PMLiVE

AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

Patients with RA reported an improvement in mobility pain on the JAK1 inhibitor

- PMLiVE

The Patient Journey

A roadmap for success

- PMLiVE

Jim Mellon’s biotech Juvenescence raises $50m for anti-ageing therapies

Billionaire's belief in emerging anti-ageing therapies fuels start up

- PMLiVE

Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom

A rapid round up of pharma, biotech and healthcare news

- PMLiVE

Wearables and healthcare

What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?

IGNIFI

- PMLiVE

Gates’ non-profit biotech for poverty diseases sets out its stall at BIO

Chief executive Heaton says GatesMRI will be a place where translational science meets medicine

- PMLiVE

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Another BACE candidate is abandoned, leaving just one remaining in the pipeline

- PMLiVE

European pharma pips North America in remote physician engagement, according to Indegene-TEVA survey

European pharma companies have outperformed their American peers in applying remote physician engagement to their multi-channel marketing mix, according to the 2018 Indegene-TEVA survey. Among popular users, 35% of the...

- PMLiVE

Daily Brief: Tagrisso’s first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS

A rapid round up of today's pharma, biotech and healthcare news

- PMLiVE

Cancer Research UK to test Asterias’ lung cancer vaccine

The vaccine could treat NSCLC patients who are at risk of relapse

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links